Hone Health’s published membership information identifies a progesterone capsule as compounded. That word changes the interpretation of an otherwise familiar medicine name. A capsule containing progesterone is not necessarily an FDA-approved generic of a branded product, even when the hormone’s identity is the same. The finished preparation and its regulatory pathway still matter.
We reviewed Hone’s menopause service, women’s Premium membership and progesterone information on September 29, 2026. This review separates the documented capsule category from the proposed treatment’s evidence, its unknown formulation and the charges surrounding it. It does not verify personal eligibility, a dispensing pharmacy, a physical package or the results of care.
Read this article by section
The membership page identifies both a route and a manufacturing category
Hone’s women’s Premium description lists a compounded oral progesterone capsule. Unlike a broad hormone menu, that wording connects the ingredient with a route and a product category. It does not name every ingredient, establish a manufacturer-specific label or guarantee that the clinician will prescribe it. The menopause service page provides the clinical context for assessment. Our Renew Youth review shows why that distinction matters when another service discusses several routes more generally. More precise terminology improves the description of an offer; it is not evidence that the treatment is safer or more effective.
Approved generic and compounded are different descriptions
FDA’s generic-drug explanation describes defined requirements for an approved generic, including its relationship to the reference drug’s active ingredient, strength, form and route. The separate compounding guidance explains that compounded medicines are not FDA approved. Hone’s capsule should therefore not be called an approved generic solely because it contains progesterone or resembles another capsule. The bioidentical approval guide helps keep these categories apart. Whether a compound is proposed for a particular clinical reason is a question for the prescriber. This review does not resolve that reason in advance or equate a familiar ingredient with a reviewed finished product.
Do not move a labeled indication onto an unidentified compound
Hone’s capsule information lists a broad cancer-prevention claim. The FDA Prometrium label, by contrast, describes prevention of endometrial hyperplasia for a specified postmenopausal population receiving conjugated estrogen tablets. That defined indication is not a general cancer-prevention guarantee and does not establish the same evidence for Hone’s compounded preparation. A clinician should connect the intended treatment purpose to the actual product and explain any limits or unapproved use. Readers comparing progesterone with other progestin terms should also avoid transferring a finding between different medicines merely because the names belong to a related category.
Capsule shape does not disclose oils, fillers or other ingredients
The Premium listing establishes an oral capsule category but does not provide a complete formulation in the reviewed description. A concern about an excipient requires information from the pharmacy about the actual prescribed preparation. The exact Prometrium label includes peanut oil, but that fact cannot be assigned to Hone’s compound or used to conclude that the compound lacks it. Similar-looking dosage forms can require different ingredient checks. The micronized guide explains why particle-processing terminology would not settle this question either. An ingredient question should remain unresolved until it is answered for the supplied product.
The estimated $49 medicine charge sits outside Premium
Hone’s membership information describes a $65 initial at-lab test charge and Premium membership at $155 per month. It separately estimates the progesterone capsule at $49 per month and a cream at $79; the medicine estimates can vary and are not included in the membership figure. The listed follow-up laboratory and consultation benefits do not convert these separate charges into one all-inclusive price. The page describes cancellation taking effect at the billing-period end. Ask for the selected plan’s full recurring terms and actual prescription quote. Neither the lower capsule estimate nor the cream’s separate figure is a basis for choosing a route. Keep the clinical and financial meanings of follow-up distinct. An included consultation is access to a review, not assurance that treatment will continue, that a medicine will be renewed unchanged or that another preparation would cost the same. If the clinician recommends a different option, request an updated medicine quote and clarification of what happens to the membership commitment. We have not tested a cancellation or established a refund outcome for an individual account; those details should come from the selected agreement.
A product-page title creates a different uncertainty at Lifeforce
Our Lifeforce review examines a page titled Micronized Progesterone whose reviewed wording leaves other product details unresolved. Hone’s compounded capsule listing answers some category questions more directly, but a comparison still needs the same level of specificity on both sides. Ask which exact preparation each clinician proposes, what its evidence supports and which service charges are compulsory. This is a document comparison, not a ranking of likely results. A membership’s name, a product-page title and an estimated medication amount describe different things and should not be combined into an apparent head-to-head price for identical treatment.
The useful question joins the evidence to the dispensed product
Before treating Hone’s capsule description as a complete medicine record, ask the clinician which preparation is intended, why that preparation is proposed and what evidence applies to the intended use. The pharmacy can then clarify the formulation and patient information accompanying it. FDA’s compounding explanation is relevant to that conversation without supplying a personal recommendation. This review establishes a menopause-care offer with an expressly compounded oral option and separately described charges. It leaves the individual treatment decision, exact excipients, pharmacy arrangements and final bill unverified. Nothing here directs a reader to substitute this option for an existing approved medicine or to change its prescribed route.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Hone Health: Menopause treatmentProvider menopause service, treatment goals and promotional timeline; not an individual outcome prediction · Checked 2026-09-29
- FDA: Generic Drugs — Questions & AnswersFDA public generic-drug explanation, updated September 18, 2026; approved-generic requirements and qualified inactive-ingredient differences, not identification or substitution advice for a particular provider prescription · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- Hone Health: Progesterone Capsule for Women, Risks and BenefitsProvider capsule benefit claims, including an unqualified cancer-prevention statement; reviewed as marketing and limited with exact FDA label context · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29